Dubus J C, Marguet C, Deschildre A, Mely L, Le Roux P, Brouard J, Huiart L
Services de Pédiatrie, CHU Timone-Enfants, Marseille, Hôpital Charles Nicolle (Rouen), Hôpital Jeanne de Flandres (Lille), Hôpital du Havre (Le Havre), CH Côte de Nâcre (Caen), INSERM U379, Institut Paoli-Calmette, Marseille, France.
Allergy. 2001 Oct;56(10):944-8. doi: 10.1034/j.1398-9995.2001.00100.x.
The objective was to investigate the local side-effects of inhaled corticosteroids (ICS) in daily life in asthmatic children, particularly the younger ones, by an observational prospective cross-sectional cohort study.
Asthmatic children (n=639, 75.9+/-48.9 months, 61.3% boys), treated with beclomethasone dipropionate (BDP) (721.0+/-287.3 microg per day) or budesonide (BUD) (835.5+/-684.9 microg per day) for at least 1 month, were recruited at the time of a scheduled visit. Local side-effects were researched by questionnaire (cough during inhalation, hoarseness, dysphonia, and thirsty feeling) and clinical examination (perioral dermatitis, oral candidiasis, and tongue hypertrophy).
Exactly 63.3% of the children aged under 6 years and 59.5% of the older ones reported one local side-effect. Cough (39.7%) was dependent on young age, use of BDP, and mainly use of spacer device, with an OR of 4.7 (95% CI: 2.7-8.2). Thirsty feeling (21.9%) and hoarseness (14.1%) occurred in children using ICS and long-acting beta2-agonists. Dysphonia (11.1%) was favored by high doses of BDP and BUD, and by inhalation from spacer devices or nebulizers. No factor favored oral candidiasis (10.7%). Perioral dermatitis (2.9%) and tongue hypertrophy (0.1%) were associated with nebulization.
Local side-effects of ICS are common in asthmatic children of all ages, and the device used constitutes the most influential factor.
通过一项观察性前瞻性横断面队列研究,调查吸入性糖皮质激素(ICS)在哮喘儿童,尤其是年幼儿童日常生活中的局部副作用。
招募了接受丙酸倍氯米松(BDP)(每日721.0±287.3微克)或布地奈德(BUD)(每日835.5±684.9微克)治疗至少1个月的哮喘儿童(n = 639,年龄75.9±48.9个月,61.3%为男孩),在预定就诊时进行研究。通过问卷调查(吸入时咳嗽、声音嘶哑、发音困难和口渴感)和临床检查(口周皮炎、口腔念珠菌病和舌肥大)来研究局部副作用。
6岁以下儿童中恰好63.3%以及年龄较大儿童中59.5%报告有一项局部副作用。咳嗽(39.7%)与年龄小、使用BDP以及主要使用储雾罐有关,比值比为4.7(95%可信区间:2.7 - 8.2)。使用ICS和长效β2受体激动剂的儿童出现口渴感(21.9%)和声音嘶哑(14.1%)。高剂量的BDP和BUD以及通过储雾罐或雾化器吸入会增加发音困难(11.1%)的发生。没有因素会增加口腔念珠菌病(10.7%)的发生。口周皮炎(2.9%)和舌肥大(0.1%)与雾化有关。
ICS的局部副作用在各年龄段的哮喘儿童中都很常见,且所使用的装置是最有影响的因素。